Skip to main content
Erschienen in: Endocrine 2/2019

28.08.2018 | Original Article

Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime

verfasst von: Fangfang Jiao, Eric Yuk Fai Wan, Colman Siu Cheung Fung, Anca Ka Chun Chan, Sarah Morag McGhee, Ruby Lai Ping Kwok, Cindy Lo Kuen Lam

Erschienen in: Endocrine | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) was found to be cost-saving in comparison with usual primary care over 5 years’ follow-up. This study aimed to estimate the cost-effectiveness of RAMP-DM over lifetime.

Methods

We built a Discrete Event Simulation model to evaluate the cost-effectiveness of RAMP-DM over lifespan from public health service provider’s perspective. Transition probabilities among disease states were extrapolated from a cohort of 17,140 propensity score matched participants in RAMP-DM and those under usual primary care over 5-year’s follow-up. The mortality of patients with specific DM-related complications was estimated from a cohort of 206,238 patients with diabetes. Health preference and direct medical costs of DM patients referred to our previous studies among Chinese DM patients.

Results

RAMP-DM individuals gained 0.745 QALYs and cost US$1404 less than those under usual care. The probabilistic sensitivity analysis found that RAMP-DM had 86.0% chance of being cost-saving compared to usual care under the assumptions and estimates used in the model. The probability of RAMP-DM being cost-effective compared to usual care would be over 99%, when the willingness to pay threshold is HK$20,000 (US$ 2564) or higher.

Conclusion

RAMP-DM added to usual primary care was cost-saving in managing people with diabetes over lifetime. These findings support the integration of RAMP-DM as part of routine primary care for all patients with diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat International Diabetes Federation: diabetes atlas seventh edition. (2015). International Diabetes Federation: diabetes atlas seventh edition. (2015).
2.
3.
Zurück zum Zitat F.G. Cleveringa, P.M. Welsing, M. van den Donk, K.J. Gorter, L.W. Niessen, G.E. Rutten, W.K. Redekop, Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care 33(2), 258–263 (2010). https://doi.org/10.2337/dc09-1232 CrossRefPubMed F.G. Cleveringa, P.M. Welsing, M. van den Donk, K.J. Gorter, L.W. Niessen, G.E. Rutten, W.K. Redekop, Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care 33(2), 258–263 (2010). https://​doi.​org/​10.​2337/​dc09-1232 CrossRefPubMed
4.
Zurück zum Zitat B.S. Chan, M.W. Tsang, V.W. Lee, K.K. Lee, Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int. J. Clin. Pharmacol. Ther. 45(8), 455–468 (2007)CrossRefPubMed B.S. Chan, M.W. Tsang, V.W. Lee, K.K. Lee, Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int. J. Clin. Pharmacol. Ther. 45(8), 455–468 (2007)CrossRefPubMed
5.
Zurück zum Zitat American Diabetes Association, Standards of medical care in diabetes 2013. Diabetes Care 36(Supplement 1), S11–S57 (2013)CrossRef American Diabetes Association, Standards of medical care in diabetes 2013. Diabetes Care 36(Supplement 1), S11–S57 (2013)CrossRef
6.
Zurück zum Zitat National Collaborating Centre for Chronic Conditions: type 2 diabetes National clinical guideline for management in primary and secondary care (update). In. Royal College of physicians, (2008). National Collaborating Centre for Chronic Conditions: type 2 diabetes National clinical guideline for management in primary and secondary care (update). In. Royal College of physicians, (2008).
7.
Zurück zum Zitat Canadian Diabetes Association, 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 32(Supplement 1), S1–S201 (2008) Canadian Diabetes Association, 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 32(Supplement 1), S1–S201 (2008)
16.
17.
Zurück zum Zitat E.Y.F. Wan, C.S.C. Fung, F.F. Jiao, E.Y.T. Yu, W.Y. Chin, D.Y.T. Fong, C.K.H. Wong, A.K.C. Chan, K.H.Y. Chan, R.L.P. Kwok, C.L.K. Lam, Five-year effectiveness of the Multidisciplinary Risk Assessment and Management Programme-diabetes mellitus (RAMP-DM) on diabetes-related complications and health service uses-a population-based and propensity-matched cohort study. Diabetes Care 41(1), 49–59 (2018). https://doi.org/10.2337/dc17-0426 CrossRefPubMed E.Y.F. Wan, C.S.C. Fung, F.F. Jiao, E.Y.T. Yu, W.Y. Chin, D.Y.T. Fong, C.K.H. Wong, A.K.C. Chan, K.H.Y. Chan, R.L.P. Kwok, C.L.K. Lam, Five-year effectiveness of the Multidisciplinary Risk Assessment and Management Programme-diabetes mellitus (RAMP-DM) on diabetes-related complications and health service uses-a population-based and propensity-matched cohort study. Diabetes Care 41(1), 49–59 (2018). https://​doi.​org/​10.​2337/​dc17-0426 CrossRefPubMed
18.
20.
Zurück zum Zitat S.J. Griffin, K. Borch-Johnsen, M.J. Davies, K. Khunti, G.E. Rutten, A. Sandbaek, S.J. Sharp, R.K. Simmons, M. van den Donk, N.J. Wareham, T. Lauritzen, Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378(9786), 156–167 (2011). https://doi.org/10.1016/S0140-6736(11)60698-3 CrossRefPubMedPubMedCentral S.J. Griffin, K. Borch-Johnsen, M.J. Davies, K. Khunti, G.E. Rutten, A. Sandbaek, S.J. Sharp, R.K. Simmons, M. van den Donk, N.J. Wareham, T. Lauritzen, Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378(9786), 156–167 (2011). https://​doi.​org/​10.​1016/​S0140-6736(11)60698-3 CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat L. Tao, E.C. Wilson, N.J. Wareham, A. Sandbaek, G.E. Rutten, T. Lauritzen, K. Khunti, M.J. Davies, K. Borch-Johnsen, S.J. Griffin, R.K. Simmons, Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet. Med. 32(7), 907–919 (2015). https://doi.org/10.1111/dme.12711 CrossRefPubMedPubMedCentral L. Tao, E.C. Wilson, N.J. Wareham, A. Sandbaek, G.E. Rutten, T. Lauritzen, K. Khunti, M.J. Davies, K. Borch-Johnsen, S.J. Griffin, R.K. Simmons, Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet. Med. 32(7), 907–919 (2015). https://​doi.​org/​10.​1111/​dme.​12711 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat T.P. Gilmer, P.J. O’Connor, J.M. Sperl-Hillen, W.A. Rush, P.E. Johnson, J.H. Amundson, S.A. Asche, H.L. Ekstrom, Cost effectiveness of an EMR-based. Diabetes Clin. Decis. Support Syst. Diabetes 59, A71–A71 (2010) T.P. Gilmer, P.J. O’Connor, J.M. Sperl-Hillen, W.A. Rush, P.E. Johnson, J.H. Amundson, S.A. Asche, H.L. Ekstrom, Cost effectiveness of an EMR-based. Diabetes Clin. Decis. Support Syst. Diabetes 59, A71–A71 (2010)
26.
Zurück zum Zitat R.J. Stevens, V. Kothari, A.I. Adler, I.M. Stratton, United Kingdom Prospective Diabetes Study, Group The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. 101(6), 671–679 (2001).CrossRefPubMed R.J. Stevens, V. Kothari, A.I. Adler, I.M. Stratton, United Kingdom Prospective Diabetes Study, Group The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. 101(6), 671–679 (2001).CrossRefPubMed
27.
Zurück zum Zitat V. Kothari, R.J. Stevens, A.I. Adler, I.M. Stratton, S.E. Manley, H.A. Neil, R.R. Holman, UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33(7), 1776–1781 (2002)CrossRef V. Kothari, R.J. Stevens, A.I. Adler, I.M. Stratton, S.E. Manley, H.A. Neil, R.R. Holman, UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33(7), 1776–1781 (2002)CrossRef
29.
Zurück zum Zitat X. Yang, W.Y. So, A.P. Kong, C.S. Ho, C.W. Lam, R.J. Stevens, R.R. Lyu, D.D. Yin, C.S. Cockram, P.C. Tong, V. Wong, J.C. Chan, Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 30(1), 65–70 (2007). https://doi.org/10.2337/dc06-1273 CrossRef X. Yang, W.Y. So, A.P. Kong, C.S. Ho, C.W. Lam, R.J. Stevens, R.R. Lyu, D.D. Yin, C.S. Cockram, P.C. Tong, V. Wong, J.C. Chan, Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 30(1), 65–70 (2007). https://​doi.​org/​10.​2337/​dc06-1273 CrossRef
30.
Zurück zum Zitat P.M. Clarke, A.M. Gray, A. Briggs, A.J. Farmer, P. Fenn, R.J. Stevens, D.R. Matthews, I.M. Stratton, R.R. Holman, Group, U.K.P.D.S. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10), 1747–1759 (2004). https://doi.org/10.1007/s00125-004-1527-z CrossRefPubMed P.M. Clarke, A.M. Gray, A. Briggs, A.J. Farmer, P. Fenn, R.J. Stevens, D.R. Matthews, I.M. Stratton, R.R. Holman, Group, U.K.P.D.S. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10), 1747–1759 (2004). https://​doi.​org/​10.​1007/​s00125-004-1527-z CrossRefPubMed
31.
Zurück zum Zitat F. Jiao, C.K.H. Wong, S.C.W. Tang, C.S.C. Fung, K.C.B. Tan, S. McGhee, R. Gangwani, C.L.K. Lam, Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong. Diabet. Med. 34(9), 1276–1283 (2017). https://doi.org/10.1111/dme.13416 CrossRefPubMed F. Jiao, C.K.H. Wong, S.C.W. Tang, C.S.C. Fung, K.C.B. Tan, S. McGhee, R. Gangwani, C.L.K. Lam, Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong. Diabet. Med. 34(9), 1276–1283 (2017). https://​doi.​org/​10.​1111/​dme.​13416 CrossRefPubMed
32.
Zurück zum Zitat F. Jiao, C.K.H. Wong, R. Gangwani, K.C.B. Tan, S.C.W. Tang, C.L.K. Lam, Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. Health Qual. Life Outcomes 15(1), 125 (2017). https://doi.org/10.1186/s12955-017-0699-4 CrossRefPubMedPubMedCentral F. Jiao, C.K.H. Wong, R. Gangwani, K.C.B. Tan, S.C.W. Tang, C.L.K. Lam, Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. Health Qual. Life Outcomes 15(1), 125 (2017). https://​doi.​org/​10.​1186/​s12955-017-0699-4 CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal 2013. (2013). National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal 2013. (2013).
34.
Zurück zum Zitat Census and Statistics Department Gross Domestic Product (GDP), implicit price deflator of GDP and per capita GDP. (2013). Census and Statistics Department Gross Domestic Product (GDP), implicit price deflator of GDP and per capita GDP. (2013).
35.
Zurück zum Zitat World Health Organization: WHO Commission on Macroeconomics and Health: Macroeconomics and health: investing in health for economic development.Report of the commission on Macroeconomics and Health: Executive Summary. World Health Organization, Geneva, (2001). World Health Organization: WHO Commission on Macroeconomics and Health: Macroeconomics and health: investing in health for economic development.Report of the commission on Macroeconomics and Health: Executive Summary. World Health Organization, Geneva, (2001).
37.
Zurück zum Zitat S. Rao Kondapally Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, N. Sarwar, P.H. Whincup, K.J. Mukamal, R.F. Gillum, I. Holme, I. Njolstad, A. Fletcher, P. Nilsson, S. Lewington, R. Collins, V. Gudnason, S.G. Thompson, N. Sattar, E. Selvin, F.B. Hu, J. Danesh; Emerging Risk Factors, C., Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364(9), 829–841 (2011). https://doi.org/10.1056/NEJMoa1008862 CrossRefPubMedPubMedCentral S. Rao Kondapally Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, N. Sarwar, P.H. Whincup, K.J. Mukamal, R.F. Gillum, I. Holme, I. Njolstad, A. Fletcher, P. Nilsson, S. Lewington, R. Collins, V. Gudnason, S.G. Thompson, N. Sattar, E. Selvin, F.B. Hu, J. Danesh; Emerging Risk Factors, C., Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364(9), 829–841 (2011). https://​doi.​org/​10.​1056/​NEJMoa1008862 CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat The World Bank: life expectancy at birth, total (years). Accessed 26 January 2016 The World Bank: life expectancy at birth, total (years). Accessed 26 January 2016
40.
Zurück zum Zitat R.C. Eastman, J.C. Javitt, W.H. Herman, E.J. Dasbach, A.S. Zbrozek, F. Dong, D. Manninen, S.A. Garfield, C. Copley-Merriman, W. Maier, J.F. Eastman, J. Kotsanos, C.C. Cowie, M. Harris, Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20(5), 725–734 (1997)CrossRefPubMed R.C. Eastman, J.C. Javitt, W.H. Herman, E.J. Dasbach, A.S. Zbrozek, F. Dong, D. Manninen, S.A. Garfield, C. Copley-Merriman, W. Maier, J.F. Eastman, J. Kotsanos, C.C. Cowie, M. Harris, Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20(5), 725–734 (1997)CrossRefPubMed
43.
Zurück zum Zitat H. Arem, S.C. Moore, A. Patel, P. Hartge, A. Berrington de Gonzalez, K. Visvanathan, P.T. Campbell, M. Freedman, E. Weiderpass, H.O. Adami, M.S. Linet, I.M. Lee, C.E. Matthews, Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA. Intern. Med. 175(6), 959–967 (2015). https://doi.org/10.1001/jamainternmed.2015.0533 CrossRef H. Arem, S.C. Moore, A. Patel, P. Hartge, A. Berrington de Gonzalez, K. Visvanathan, P.T. Campbell, M. Freedman, E. Weiderpass, H.O. Adami, M.S. Linet, I.M. Lee, C.E. Matthews, Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA. Intern. Med. 175(6), 959–967 (2015). https://​doi.​org/​10.​1001/​jamainternmed.​2015.​0533 CrossRef
Metadaten
Titel
Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime
verfasst von
Fangfang Jiao
Eric Yuk Fai Wan
Colman Siu Cheung Fung
Anca Ka Chun Chan
Sarah Morag McGhee
Ruby Lai Ping Kwok
Cindy Lo Kuen Lam
Publikationsdatum
28.08.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1727-9

Weitere Artikel der Ausgabe 2/2019

Endocrine 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.